2020
DOI: 10.5588/ijtld.20.0141
|View full text |Cite
|
Sign up to set email alerts
|

Introducing new and repurposed TB drugs: the endTB experience

Abstract: In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major implementation challenges encountered in 17 endTB countries. We provide insights on how national TB programmes and other stakeholders can scale-up the programmatic use of new and repurposed TB drugs, while building scientific evidence about their safety and efficacy. For any new drug or diagnostic, multiple market barriers can sl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 0 publications
0
3
0
1
Order By: Relevance
“…Despite a heterogeneous study population from 16 countries, monitoring and reporting were highly uniform. Distinct from prior observational reports [ 9–14 ], the present study deployed a single, externally supported monitoring schedule that included monthly electrocardiograms and audiometry, reported solicited and unsolicited AEs, used standardized a priori definitions of AEs of interest, graded events according to a single severity scale, and received support from a central PV unit [ 4 , 15 , 16 ].…”
Section: Discussionmentioning
confidence: 99%
“…Despite a heterogeneous study population from 16 countries, monitoring and reporting were highly uniform. Distinct from prior observational reports [ 9–14 ], the present study deployed a single, externally supported monitoring schedule that included monthly electrocardiograms and audiometry, reported solicited and unsolicited AEs, used standardized a priori definitions of AEs of interest, graded events according to a single severity scale, and received support from a central PV unit [ 4 , 15 , 16 ].…”
Section: Discussionmentioning
confidence: 99%
“…The possibility of increased rates of cardiotoxicity have limited co-administration of Bdq and Dlm to situations where all other treatment options are exhausted [ 2 ]. Many clinicians and National TB Programs in the areas hardest hit by MDR/RR-TB continue to avoid using Bdq and Dlm in combination out of fear of their potential overlapping toxicity [ 3 ]. Widespread concomitant use is also hampered by limited access to the drugs, especially Dlm, in part related to its high cost, and to the restricted recommendations for its use in international guidelines for MDR/RR-TB treatment [ 4 ].…”
mentioning
confidence: 99%
“…Pasien TB MDR menerima jenis obat sebanyak 7 jenis obat TB MDR terdiri atas 4 jenis obat lini kedua ditambah 3 jenis obat lini pertama atau jenis obat baru yang masih sensitif. Kombinasi tersebut untuk memperkuat obat TB MDR melawan kuman M.tuberculosis yang telah resisten (Seung et al, 2020). Pada penelitian ini jenis obat yang diterima pasien kategori <10 jenis obat sebanyak 63 pasien (53,80%).…”
Section: Gambar 4 Grafik Persentase Penggunaan Obat Tb Mdr Berdasarka...unclassified